Elekta AB Class B
EKTAF
Market Cap$1.84B
Close$
$3.50
32.2% downside
Current Fair Value
32.2% downsideOvervalued by 32.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.84 Billion |
|---|---|
| Enterprise Value | $7.11 Billion |
| Dividend Yield | $0.11072 (7.178464606181451%) |
| Earnings per Share | $3.41 |
| Beta | 1.12 |
| Outstanding Shares | 382,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 18.46 |
|---|---|
| PEG | -48.11 |
| Price to Sales | 0.11 |
| Price to Book Ratio | 0.18 |
| Enterprise Value to Revenue | 0.4 |
| Enterprise Value to EBIT | 3.62 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 1.25 |
| Debt to Equity | 0.82 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Elekta AB
CEO: Gustaf Salford Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...